Up to 2% of the adult population will suffer from a leg ulcer, with higher incidence in females. These figures may be as high as 3%-5% in those aged 65 or more (approx. 80 million individuals are over 65 in EU 28, according to Eurostat).
In the US, chronic leg and foot ulcers affect approx. 7 million people a year (and are becoming more prevalent as the US population age increases.
FB Plus can be indicated for use in up to 90% of patients with chronic leg and foot ulcers.
THE CHALLENGE
Chronic lower extremity ulcers are a big challenge to health care systems worldwide for their high frequency and for the still largely unmetcure. The total incidence of chronic wounds is estimated between 3% and 5% of total health care cost in Europe, whith a healthcare cost between €19 to €38 billion.
THE TREND
The trend in the market for the treatment of chronic injuries is a function of the growth of the population aged 65 and over. In the EU, this segment will account for a quarter of the total in 2030.
Patients’ conditions and their wounds are becoming increasingly complex, with 76% of patients with a chronic wound having three or more comorbidities and up to 46% with diabetes.
In addition, 52% of the adult population across Europe are overweight. This has an impact on the prevalence of unhealed wounds as there is a direct association between non-healing wounds and chronic diseases.